Search

Displaying results 3401 - 3410 of 4539 in total
  1. Drug

    EP-2104R

    go.drugbank.com/drugs/DB05675
    Experimental

    It is being developed by EPIX Pharmaceuticals, Inc.

  2. Drug

    BI 4060107

    go.drugbank.com/drugs/DB33963
    Experimental

    BI 4060107 is under investigation in clinical trial NCT07827144 (A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)).

  3. Drug

    Talnetant

    go.drugbank.com/drugs/DB06429
    Investigational

    Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential

  4. Drug

    (S)-Warfarin

    go.drugbank.com/drugs/DB14055
    Investigational

    Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.

    Categories: Vitamin K Antagonists
  5. Drug

    Jaktinib

    go.drugbank.com/drugs/DB17545
    Investigational

    Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals.

  6. Drug

    Asundexian

    go.drugbank.com/drugs/DB19088
    Investigational

    Asundexian is under investigation in clinical trial NCT05686070 (A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk

  7. Drug

    Autologous Non-Hematopoietic Peripheral Blood Stem Cells

    go.drugbank.com/drugs/DB15867
    Investigational

    Autologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center.

  8. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

  9. Drug

    IDM-1

    go.drugbank.com/drugs/DB05292
    Experimental

    It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.

  10. Drug

    Glucose-6-Phosphate

    go.drugbank.com/drugs/DB03581
    Experimental

    An ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells.